The IL3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line. The product features targeted disruption of the IL3 gene, which encodes interleukin-3, a key hematopoietic cytokine. As a polyclonal pool, this population encompasses a spectrum of genetic edits, providing a robust loss-of-function model free of clonal selection bias. This format is optimal for bulk assays where population-level ablation of IL3 signaling is assessed.
The A-549 cell line, originally isolated from a human lung carcinoma, serves as a widely used model of alveolar epithelial cells and non-small cell lung adenocarcinoma. A-549 cells display epithelial morphology and express markers of type II pneumocytes, making them relevant for studies of respiratory biology and oncogenesis. Their established use in cancer research includes investigations of proliferation, apoptosis, and drug response. Although IL3 signaling is predominantly hematopoietic, A-549 cells offer a unique non-hematopoietic context to explore cytokine receptor pathways.
IL3 functions as a growth factor that binds to the alpha subunit of its receptor (IL3RA/CD123), inducing heterodimerization with CSF2RB (CD131) and activating JAK2. This triggers phosphorylation of STAT5 and STAT3, leading to transcription of survival and proliferation genes such as BCL2, MYC, and CCND1. JAK2 also couples to the MAPK/ERK cascade via SHC1-GRB2-RAS-RAF-MEK and to the PI3K-AKT pathway through PIK3R1. Upstream, IL3 expression is regulated by NF-??B, AP-1, NFAT, and T-cell receptor-derived signals. Key interacting partners include JAK2, SHC1, GRB2, and PIK3R1, collectively mediating IL3-dependent cell fate decisions.
In A-549 cells, knockout of IL3 allows investigation of cytokine signaling contributions to lung adenocarcinoma phenotypes, particularly if IL3 receptor components are ectopically or endogenously expressed. This model enables dissection of autocrine or paracrine loops potentially affecting tumor cell proliferation and drug sensitivity. By disrupting IL3, researchers can examine STAT5, ERK, and AKT pathway outputs in a lung cancer background, independent of hematopoietic factors. The polyclonal format reduces clonal variability and enhances reproducibility in signaling and transcriptomic analyses.
These IL3-knockout polyclonal cells support a range of applications, including Western blotting for phospho-STAT5 and phospho-ERK, RT-qPCR for downstream targets like CCND1, and proliferation or colony formation assays. They are also suitable for RNA-seq, cytokine profiling, and drug sensitivity studies to explore the role of IL3 in modulating therapeutic responses. This product serves as a versatile tool for functional genomics and cancer signaling research. For further inquiries, contact Ascent Research.
